Long-acting β2-agonists in the management of asthma exacerbations

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Purpose of review: Asthma exacerbations are a major cause of mortality in the United States. Although long-acting β2-agonists have a defined role in maintenance therapy, their potential use in exacerbations remains largely undetermined. This paper reviews recent literature on long-acting β2-agonists in the context of the management of acute asthma. Recent findings: Although clinical experience with long-acting β2-agonists now approaches 20 years, their applicability in asthma exacerbations has only recently been explored. Formoterol, with a rapid onset of action similar to albuterol, has already been approved in Europe as a reliever medication and there are emerging data to support its use in the outpatient management of mild exacerbations of asthma. Salmeterol added to conventional therapy has been found to be safe and potentially beneficial in patients hospitalized for an exacerbation. Summary: Long-acting β2-agonists have proved to be useful in the chronic management of asthma and the prevention of exacerbations. Recent data suggest a role for patient-guided management using adjustable dosing of long-acting β2-agonists with inhaled corticosteroids during periods of worsening asthma. Further research to evaluate the potential role of long-acting β2-agonists in the management of acute asthma is needed.

Original languageEnglish (US)
Pages (from-to)69-73
Number of pages5
JournalCurrent Opinion in Pulmonary Medicine
Volume11
Issue number1
StatePublished - Jan 1 2005

Keywords

  • Asthma exacerbation
  • Formoterol
  • Long-acting β-agonists
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Long-acting β<sub>2</sub>-agonists in the management of asthma exacerbations'. Together they form a unique fingerprint.

Cite this